Skip to content
Screener

Dyne Therapeutics, Inc. DYN Financing Cash Flow

Financing Cash Flow at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$241K-98.1%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$412.29M-33,163%
Arrowhead Research logo
Arrowhead ResearchARWR
$795.72M+761%
Wave Life Sciences logo
Wave Life SciencesWVE
$330K-97.2%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$48.47M
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
$12.17M+448%

Other financials

Income statement

See full
Operating income-$125.3M-2.4%
Net income-$120.9M-4.8%
EPS (diluted)-$0.73+30.5%

Balance sheet

See full
Cash & equivalents$753.1M+59.5%
Total debt$168.7M+623%
Total equity$865.1M+29.3%
Total assets$1.1B+49.8%

Cash flow

See full
Operating cash flow-$144.9M-36.9%
CapEx$221.0K-77.5%
Free cash flow-$145.1M-35.8%

Valuation

See full
Market cap$4.83B+193%
Enterprise value$4.25B+231%

Returns & leverage

See full
Return on equity-58.9%-4.4pp
Debt / equity0.2×+0.2×
Current ratio19.9×-0.4×

Where this comes from

Reported directly by Dyne Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 7:25 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-215702
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Proceeds from vendor financing arrangement6,786
Repayments under vendor financing arrangement(579)
Proceeds from issuance of common stock in at-the-market offering, net of issuance costs140,653
Net cash provided by financing activities7,064141,241
Net increase (decrease) in cash, cash equivalents and restricted cash(140,250)36,806
Cash, cash equivalents and restricted cash, beginning of period895,740437,391
Cash, cash equivalents and restricted cash, end of period$755,490$474,197
Supplemental disclosures of cash flow information:

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Dyne Therapeutics, Inc.'s financing cash flow?
Dyne Therapeutics, Inc. (DYN) reported financing cash flow of $7.06M in Q1 2026.
How has Dyne Therapeutics, Inc.'s financing cash flow changed year-over-year?
Dyne Therapeutics, Inc.'s financing cash flow decreased by 95.0% year-over-year, from $141.24M to $7.06M.
What is the long-term trend for Dyne Therapeutics, Inc.'s financing cash flow?
Over 4 years (2021 to 2025), Dyne Therapeutics, Inc.'s financing cash flow has grown at a 54.1% compound annual growth rate (CAGR), from $157.82M to $890.31M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Dyne Therapeutics, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude